BioNexus Expands into Ethereum and Renewable Energy

Introduction

BioNexus Gene Lab Corp. (NASDAQ: BGLC) is a biotechnology and chemical-materials supplier headquartered in Kuala Lumpur, Malaysia. As of July 1, 2025, its shares traded at USD 12.78, reflecting a 316.29 percent increase over the prior period, with a daily volume of 4,294,099 shares. The company’s core technology—blood-based genomic screening—analyzes circulating RNA to assess risk for eight common cancers, two inflammatory diseases, and osteoarthritis.

Corporate Structure and Experience

Founded in 2017, BioNexus Gene Lab Corp. operates two main segments: a biotech arm (BioNexus Malaysia) focused on molecular diagnostics and a chemical-supply unit (Chemrex) serving industrial and medical markets. The firm employs between 11 and 50 professionals, including a leadership team with backgrounds in molecular medicine and biomedical research. Co-founder Late Professor Dato’ Dr. Liew Choong-Chin was involved in clinical genome screening, while the current CEO, Lee Su-Leng Tan, oversees both diagnostics and raw materials businesses. A key subsidiary, MRNA Scientific Sdn. Bhd., drives partnerships in precision medicine and regenerative therapies.

Genomic screening by CDC

Recent Developments and News

On September 12, 2024, BioNexus signed a memorandum of understanding with Shenzhen Rongguang Health Group to expand cancer screening, precision medicine, and preventative healthcare solutions across China and Southeast Asia. Thirteen days later, on September 25, 2024, the company’s MRNA Scientific subsidiary entered a three-year teaming agreement with Protech Builders Sdn. Bhd. to develop biogas plants from plantation wastewater, with an initial joint contribution of RM 1,000,000 (approximately USD 235,000) for feasibility studies.

On March 6, 2025, the board approved an Ethereum-focused treasury strategy, becoming the first Nasdaq-listed firm to designate ETH as a primary corporate treasury asset, concurrent with the publication of its Ethereum Strategy Whitepaper. On March 7, 2025, BioNexus partnered with ML Tech to optimize yield and risk management of its Ethereum holdings. Subsequently, on April 3, 2025, Nasdaq issued an alert detailing a reverse stock split and CUSIP number change for BGLC.

Financial filings further document corporate activity: the Form 10-Q dated May 15, 2025, covers first-quarter results, and a Form 8-K filed June 23, 2025, reports executive appointments and other material disclosures under Items 5.02 and 9.01.

Financial and Strategic Analysis

As of mid-2025, BioNexus carries a market capitalization of approximately USD 5.52 million, a 0.51 percent increase over the prior week. The company’s trailing-quarter net loss reached USD 623,330, compared with a loss of USD 348,320 in the previous quarter (a 78.95 percent increase). EBITDA for the period stood at –USD 2.13 million, representing an EBITDA margin of –18.96 percent. The stock exhibits 22.45 percent volatility and a beta coefficient of 0.79. Technical indicators over one-week and one-month horizons show neutral and sell signals, respectively.

Strategically, BioNexus is diversifying into renewable energy through biogas infrastructure and into digital assets through its Ethereum treasury. Collaborations in precision medicine and regenerative therapies, particularly with Shenzhen Rongguang, aim to broaden diagnostic and treatment offerings. The chemical-materials segment provides cash-flow stability while biotech initiatives focus on early detection and preventative health solutions.

Market Position and Industry Context

BioNexus occupies a niche at the intersection of genomics and healthcare technology. Its blood-based genomic screening (BGS) test leverages RNA dynamics to detect disease predispositions ahead of symptoms. Within Southeast Asia’s growing biotech sector, BGLC competes with both established diagnostic labs and emerging liquid-biopsy firms. Its dual role as a chemical-materials supplier mitigates reliance on a single revenue stream. Public trading on NASDAQ provides access to U.S. capital markets, although the company’s small-cap profile and negative earnings categorize it within higher-risk, early-stage biotechs. Strategic partnerships in renewable energy and blockchain indicate an effort to expand beyond core diagnostics into adjacent markets.

tl;dr

On March 6, 2025, BioNexus’s board approved an Ethereum-focused treasury strategy and released a whitepaper explaining its rationale. The following day, the company engaged ML Tech to implement yield optimization and risk management protocols for its ETH holdings. A reverse stock split and CUSIP change were announced by Nasdaq on April 3, 2025. Concurrently, feasibility studies under the RM 1,000,000 biogas agreement with Protech Builders are underway, and partnerships in precision medicine with Shenzhen Rongguang aim to drive growth in diagnostic services through 2027.